Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Ltd announced the cessation of Douglas Cubbin as a director of the company as of November 19, 2025. This change in the board may impact the company’s strategic direction and governance. The announcement also detailed Cubbin’s interests in the company’s securities, including the lapse of 12,500 unlisted options upon his departure. The update is significant for stakeholders as it reflects changes in leadership and potential shifts in company policy or focus.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a company operating in the medical industry, focusing on the development and commercialization of medical devices for the treatment of cancer. Its primary product is a targeted radioactive implant designed to treat pancreatic and liver cancer, aiming to improve patient outcomes in these specific areas of oncology.
Average Trading Volume: 23,358
Technical Sentiment Signal: Sell
Current Market Cap: A$21.65M
Find detailed analytics on OSL stock on TipRanks’ Stock Analysis page.